The RED-HF investigators noted that this observation was consistent with an elevated risk for stroke associated with darbepoetin alfa found in the TREAT trial of patients with diabetes, chronic kidney disease, and anemia.

FORBES: Yet Another Negative Trial For Amgen's Aranesp